Analysts expect Cryoport, Inc. (NASDAQ:CYRX) to report ($0.15) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for Cryoport’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.18). Cryoport reported earnings per share of ($0.29) in the same quarter last year, which suggests a positive year over year growth rate of 48.3%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 4th.
On average, analysts expect that Cryoport will report full year earnings of ($0.57) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.47). For the next financial year, analysts forecast that the company will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.67) to ($0.20). Zacks’ EPS calculations are an average based on a survey of research firms that follow Cryoport.
Cryoport (NASDAQ:CYRX) last announced its earnings results on Thursday, August 5th. The consumer goods maker reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). Cryoport had a positive return on equity of 2.35% and a negative net margin of 18.85%.
In related news, Director Daniel M. Hancock sold 12,850 shares of the company’s stock in a transaction dated Tuesday, June 22nd. The stock was sold at an average price of $65.75, for a total value of $844,887.50. Following the completion of the transaction, the director now owns 17,477 shares of the company’s stock, valued at approximately $1,149,112.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert Stefanovich sold 50,000 shares of the company’s stock in a transaction dated Thursday, July 15th. The stock was sold at an average price of $54.03, for a total value of $2,701,500.00. Following the completion of the transaction, the chief financial officer now directly owns 61,417 shares of the company’s stock, valued at approximately $3,318,360.51. The disclosure for this sale can be found here. Insiders have sold a total of 412,750 shares of company stock worth $24,624,330 over the last ninety days. 10.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYRX. FORA Capital LLC acquired a new position in shares of Cryoport during the first quarter valued at approximately $35,000. Sowell Financial Services LLC raised its holdings in shares of Cryoport by 1,907.3% during the first quarter. Sowell Financial Services LLC now owns 823 shares of the consumer goods maker’s stock valued at $51,000 after acquiring an additional 782 shares during the last quarter. Eaton Vance Management acquired a new stake in shares of Cryoport in the first quarter valued at approximately $56,000. FinTrust Capital Advisors LLC increased its holdings in shares of Cryoport by 199.6% in the second quarter. FinTrust Capital Advisors LLC now owns 1,504 shares of the consumer goods maker’s stock valued at $95,000 after purchasing an additional 1,002 shares during the last quarter. Finally, Psagot Investment House Ltd. increased its holdings in shares of Cryoport by 22.4% in the first quarter. Psagot Investment House Ltd. now owns 1,952 shares of the consumer goods maker’s stock valued at $102,000 after purchasing an additional 357 shares during the last quarter. 87.29% of the stock is owned by institutional investors.
Shares of Cryoport stock traded down $1.15 on Friday, reaching $64.70. The company had a trading volume of 327 shares, compared to its average volume of 434,746. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -34.66 and a beta of 0.89. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.79 and a quick ratio of 10.49. The firm’s 50-day moving average price is $60.48 and its two-hundred day moving average price is $57.50. Cryoport has a 1 year low of $39.10 and a 1 year high of $84.97.
Cryoport Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Article: Operating Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.